Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.44 |
| ▸ | CALML3 | P27482 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410528 | 0.87 | MAOB (0.57) | MAOACALML3MAOBKCNH2 | |
| SCHEMBL18410621 | 0.85 | MAOA (0.60) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL18410531 | 0.85 | MAOA (0.60) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL18410652 | 0.85 | MAOA (0.48) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL18408849 | 0.85 | MAOA (0.48) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL18408843 | 0.85 | CALML3 (0.41) | MAOACALML3MAOBCYP3A4CYP2D6 | |
| SCHEMBL24296584 | 0.84 | CALML3 (0.51) | MAOACALML3MAOBCYP3A4 | |
| SCHEMBL4015562 | 0.84 | MAOA (0.50) | MAOACALML3MAOB | |
| SCHEMBL4017066 | 0.83 | MAOA (0.58) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL18396817 | 0.83 | MAOB (0.54) | MAOACALML3MAOBCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOA 2234/4885CALML3 4026/4885MAOB 1541/4885 |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOA 2234/4885CALML3 4026/4885MAOB 1541/4885 |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | MAOA 2234/4885CALML3 4026/4885MAOB 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.